newsfilter
← Earnings
Earnings Releases·

ALX Oncology — Third Quarter 2026 Earnings Summary

  • Cash and investments increased to $147.2 million as of September 30, 2026, from $48.3 million in December 2025, providing sufficient funding for operations through the first half of 2028.
  • GAAP net loss narrowed to $21.8 million ($0.15 per share) for the three months ended September 30, 2026, compared to $22.1 million ($0.41 per share) in the prior-year period, while nine-month GAAP net loss decreased to $57.7 million from $78.8 million.
  • Topline data for the Phase 2 ASPEN-09-Breast trial is expected in the second half of 2027, with safety and early efficacy data for the ALX2004 Phase 1 study anticipated in December 2026.
  • Evorpacept data from the Phase 2 ASPEN-06 trial was published in *Nature Medicine* showing improved response rates in HER2-positive gastric cancers, supported by FDA Fast Track and Orphan Drug Designations.
Company
ALX ONCOLOGY HOLDINGS INC
Sector
Healthcare
Industry
Biotechnology